Editor, Editors, USER, admin, Bureaucrats, Check users, dev, editor, founder, Interface administrators, oversight, Suppressors, Administrators, translator
10,784
edits
Line 1: | Line 1: | ||
{{Main menu}} | {{Main menu}} | ||
{{ArtBy|||autore=Silvia Natoli|autore2=Cesare Iani|autore3=Massimo Tolu|autore4=Antonio Pisani}} | {{ArtBy|||autore=Silvia Natoli|autore2=Cesare Iani|autore3=Massimo Tolu|autore4=Antonio Pisani}} | ||
Glutamic acid is the most widespread excitatory neurotransmitter in the Central Nervous System (CNS), playing a critical role in numerous physiological and pathological processes. The discovery of metabotropic glutamate receptors (mGlu), a class of G-protein-coupled receptors, has led to extensive research exploring their function in both normal and diseased states. These receptors are divided into ionotropic and metabotropic types, with the latter being further subdivided into three groups based on their structure and function. | |||
Group I mGlu receptors (mGlu1 and mGlu5) are involved in modulating neuronal excitability by activating ion channels, contributing to the pathogenesis of various CNS disorders such as epilepsy, ischemia, and neurodegenerative diseases. Recent studies highlight their involvement in nociceptive transmission, showing that they play a crucial role in pain signaling at both spinal and cortical levels. Their activation can influence both ionotropic and metabotropic receptor pathways, leading to excitotoxicity, a key factor in neuronal injury during conditions like stroke, Parkinson’s, and Alzheimer’s disease. | |||
Experimental evidence also suggests that Group I mGlu receptors significantly impact nociceptive pathways, contributing to both central and peripheral pain transmission. In spinal cord and peripheral nerve studies, antagonists of mGlu receptors have shown potential in reducing hyperalgesia and inflammatory pain, offering new insights into analgesic therapy development. | |||
In conclusion, understanding the function of mGlu receptors, particularly Group I, has deepened over recent years, identifying them as important modulators of glutamatergic transmission in the CNS. These receptors hold great promise as therapeutic targets for treating CNS disorders and pain management, highlighting their potential in developing novel neuroprotective and analgesic treatments. | |||
==Glutamic Acid as a Key Excitatory Neurotransmitter== | ==Glutamic Acid as a Key Excitatory Neurotransmitter== |
edits